Prostatic Cancer

Oncology

Prevalence

143.5 / 100K

Incidence

18.4 / 100K/yr

25 drugs in development·9 companies·1 clinical trial

Drug Pipeline by Phase

Approved(1)

Drug	Company
leuprolide	SUNSET ISLAND GROUP (SUN)

Phase 3(8)

Drug	Company
Abiraterone	Merck & Co., Inc. (MRK)
Enzalutamide	Merck & Co., Inc. (MRK)
MK-5684	Merck & Co., Inc. (MRK)
new formulation of niraparib	GH Research PLC (GHRS)
New Formulation of Niraparib and Abiraterone Acetate	Janux Therapeutics, Inc. (JANX)
Niraparib	Janux Therapeutics, Inc. (JANX)
Niraparib	Merus N.V. (MRUS)
Niraparib	Myovant Sciences Ltd. (MYOV)

Phase 2(12)

Drug	Company
aaa617	Novartis AG (NVS)
Abiraterone	MACROGENICS INC (MGNX)
Enzalutamide	MACROGENICS INC (MGNX)
JSB462	Novartis AG (NVS)
Lorigerlimab	MACROGENICS INC (MGNX)
vobramitamab duocarmazine	MACROGENICS INC (MGNX)
vobramitamab duocarmazine	KYNTRA BIO INC. (KYNB)
Vobramitamab Duocarmazine (vobra duo)	MACROGENICS INC (MGNX)
vobramitamab duocarmazine 2.0 mg	KYNTRA BIO INC. (KYNB)
vobramitamab duocarmazine 2.0 mg	MACROGENICS INC (MGNX)
vobramitamab duocarmazine 2.7 mg	KYNTRA BIO INC. (KYNB)
vobramitamab duocarmazine 2.7 mg	MACROGENICS INC (MGNX)

Phase 1(1)

Drug	Company
jsb462	Novartis AG (NVS)

Phase 1/Phase 2(1)

Drug	Company
ifinatamab deruxtecan	Merck & Co., Inc. (MRK)

Phase 4(2)

Drug	Company
AAA617	Novartis AG (NVS)
GnRH agonist/antagonist	KYNTRA BIO INC. (KYNB)

BioSniper tracks 25 drugs in development for Prostatic Cancer across 9 companies.

There are 1 clinical trial targeting Prostatic Cancer tracked by BioSniper.

The estimated prevalence of Prostatic Cancer is approximately 143.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.